Contact Us
Drug Search Results
More Filters [+]

Tivozanib

Alternative Names: tivozanib, av-951, krn951, fotivda
Latest Update: 2024-09-03
Latest Update Note: News Article

Product Description

Mechanisms of Action: VEGF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Spain | Sweden | United Kingdom | United States

Approved Indications: Renal Cell Carcinoma | Oncology Unspecified

Known Adverse Events: Hypertension | Stomatitis | Hypothyroidism | Dysphonia | Diarrhea

Company: AVEO
Company Location: BOSTON MA 02108
Company CEO: Michael Bailey
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tivozanib

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Chile, Czech Republic, France, Germany, Italy, Mexico, Poland, Portugal, Spain, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Renal Cell Carcinoma

Phase 2: Adenocarcinoma|Bile Duct Cancer|Breast Cancer|Cholangiocarcinoma|Gallbladder Cancer|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Sarcoma|Soft Tissue Cancer|Vulvar Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCI-2023-07385

P2

Recruiting

Renal Cell Carcinoma

2026-11-01

2021-000050-26

P3

Active, not recruiting

Renal Cell Carcinoma

2025-09-30

UF-STO-ETG-003

P2

Recruiting

Neuroendocrine Tumors|Sarcoma|Adenocarcinoma|Cholangiocarcinoma|Ovarian Cancer|Gallbladder Cancer|Soft Tissue Cancer|Prostate Cancer|Neuroendocrine Carcinoma|Pancreatic Cancer|Vulvar Cancer|Breast Cancer|Bile Duct Cancer

2024-12-01

TiNivo-2

P3

Active, not recruiting

Renal Cell Carcinoma

2024-08-01

44%

Recent News Events

Date

Type

Title

09/03/2024

News Article

 AVEO Oncology, an LG Chem company, Announces Acceptance of Late-Breaking Oral Presentation of TiNivo-2 Results at ESMO 2024

07/18/2024

News Article

 AVEO Oncology, an LG Chem company, Announces Phase 3 Renal Cell Carcinoma Clinical Trial (TiNivo-2) Results

06/13/2024

News Article

 LG Chem company and AVEO Oncology Announce LG Chem's First Proprietary Anti-Cancer Compound enters Phase 1 Clinical Study, Dosing Initiated in the U.S.

05/08/2024

News Article

 Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions